Pregabalin Capsule
Product Images NDC 63629-8195

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 63629-8195). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl636298195)

Pregabalin Capsules 50 mg oral capsules label by Bryant Ranch Prepack. The label shows the product name, strength, and quantity of 30 capsules. It includes storage instructions and a barcode. The labeler is BRP Pharmaceuticals, and the NDC is 63629-8195-01.*

FDA Label Image

Lbl6362981952

Pregabalin 50 mg capsule label by Bryant Ranch Prepack, indicating it is a Human Prescription Drug (CV schedule). The label specifies a white capsule and includes storage instructions to keep at room temperature (20°-25°C). The package contains 30 capsules. The NDC number is 63629-8195-1, with a lot number visible and a barcode at the bottom.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line graph showing the percent of patients improved plotted against percent improvement in pain from baseline. Four lines represent different treatments: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo. The graph compares patient pain improvement across these dose groups.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A line graph comparing the percent of patients improved by percent improvement in pain from baseline between Pregabalin 100 mg taken three times a day and placebo. The y-axis shows the percent of patients improved, while the x-axis shows percent improvement in pain, with data plotted for different thresholds of percent improvements.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at doses of 75 mg, 150 mg, and 300 mg taken two times a day, compared to placebo. The graph includes four distinct trend lines with axes labeled for percent improvement and percent of patients.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

A line graph depicting the percent of patients improved based on their percent improvement in pain from baseline. The graph compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, showing higher improvement percentages in the Pregabalin groups compared to placebo.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line graph showing percent of patients improved versus percent improvement in pain from baseline. It compares Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, illustrating different levels of pain improvement among these groups.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

Bar chart comparing responder rates (%) by treatment group in two studies (E1 and E3) of Pregabalin. Study E1 groups include placebo and various doses from 50mg/day to 600mg/day all given BID. Study E3 groups include placebo, 300mg/day BID, and 600mg/day TID. Statistically significant increases in responder rates vs. placebo are indicated for most treatment groups.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A line chart showing seizure reduction as median percentage change from baseline plotted against dose (mg/day). It compares four studies identified by different markers (Study E1 BD, Study E2 TID, Study E3 BD, Study E3 TID). P-values for statistical significance are annotated along the dose points. Dose 0 corresponds to placebo.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line graph showing percent of patients improved by percent improvement in pain from baseline. It compares Pregabalin daily doses of 300 mg, 450 mg, and 800 mg against placebo. The y-axis represents percent of patients improved, from 0 to 100%, and the x-axis shows percent improvement in pain from baseline, ranging from greater than 0 to 100%. Multiple curves are displayed representing each treatment group.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A line graph comparing the estimated percentage of subjects without LTR over 180 days between Pregabalin and Placebo groups. The vertical axis shows the estimated percentage from 0% to 100%, while the horizontal axis represents time in days. The Pregabalin group line remains higher throughout the period than the Placebo group, indicating a difference in outcomes over time.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A line graph comparing the percent of subjects improved over time from baseline to week 12 between Pregabalin and placebo groups. The x-axis represents percent improvement and the y-axis percent of subjects improved. Pregabalin shows higher improvement rates than placebo throughout the range shown.*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line chart comparing the percentage of subjects improved from baseline to week 16, showing two lines representing Pregabalin and Placebo effects. The horizontal axis shows percent improvement from 0 to 100%, and the vertical axis displays the percent of subjects improved. Pregabalin consistently shows a higher percent of subjects improved compared to placebo across improvement thresholds.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

A formula for calculating creatinine clearance (CLcr) based on age, weight, serum creatinine, and a gender adjustment factor. It shows age in years multiplied by weight in kilograms, divided by 72 times serum creatinine in mg/dL, with a multiplier of 0.85 for female patients.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure of Pregabalin, showing its molecular arrangement with key functional groups including carboxylic acid and amine.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.